CH1143977H1 - 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite - Google Patents

2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite Download PDF

Info

Publication number
CH1143977H1
CH1143977H1 CH00900082T CH00900082T CH1143977H1 CH 1143977 H1 CH1143977 H1 CH 1143977H1 CH 00900082 T CH00900082 T CH 00900082T CH 00900082 T CH00900082 T CH 00900082T CH 1143977 H1 CH1143977 H1 CH 1143977H1
Authority
CH
Switzerland
Prior art keywords
benzoxazine
obesity
oxy
ones
treatment
Prior art date
Application number
CH00900082T
Other languages
English (en)
Inventor
Harold Francis Hodson
Robert Downham
Timothy John Mitchell
Beverley Jane Carr
Christopher Robert Dunk
Richard M J Palmer
Original Assignee
Alizyme Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9900413.7A external-priority patent/GB9900413D0/en
Priority claimed from GBGB9917294.2A external-priority patent/GB9917294D0/en
Application filed by Alizyme Therapeutics Ltd filed Critical Alizyme Therapeutics Ltd
Publication of CH1143977H1 publication Critical patent/CH1143977H1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CH00900082T 1999-01-08 2000-01-06 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite CH1143977H1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9900413.7A GB9900413D0 (en) 1999-01-08 1999-01-08 Inhibitors
GBGB9917294.2A GB9917294D0 (en) 1999-07-22 1999-07-22 Inhibitors
PCT/GB2000/000032 WO2000040247A1 (fr) 1999-01-08 2000-01-06 2-amino-4h-3,1-benzoxazine-4-ones destinees au traitement de l'obesite

Publications (1)

Publication Number Publication Date
CH1143977H1 true CH1143977H1 (fr) 2007-02-15

Family

ID=26314965

Family Applications (1)

Application Number Title Priority Date Filing Date
CH00900082T CH1143977H1 (fr) 1999-01-08 2000-01-06 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite

Country Status (24)

Country Link
US (4) US6624161B2 (fr)
EP (1) EP1143977B3 (fr)
JP (1) JP3822439B2 (fr)
KR (1) KR100678998B1 (fr)
CN (2) CN1915981B (fr)
AR (1) AR022204A1 (fr)
AT (1) ATE293447T1 (fr)
AU (1) AU765147C (fr)
CA (1) CA2359819C (fr)
CH (1) CH1143977H1 (fr)
DE (1) DE60019555C5 (fr)
DK (1) DK1143977T3 (fr)
ES (1) ES2240052T7 (fr)
HK (1) HK1047588B (fr)
HU (1) HUP0105003A3 (fr)
MX (1) MXPA01006921A (fr)
MY (1) MY122578A (fr)
NO (1) NO333922B1 (fr)
NZ (1) NZ512740A (fr)
PL (1) PL207383B1 (fr)
PT (1) PT1143977E (fr)
RU (1) RU2245331C2 (fr)
SI (1) SI1143977T1 (fr)
WO (1) WO2000040247A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022204A1 (es) * 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
GB0001572D0 (en) 2000-01-24 2000-03-15 Alizyme Therapeutics Ltd Inhibitors
US6504028B2 (en) * 2000-07-11 2003-01-07 The Procter & Gamble Co. Process for preparing benzoxazin-4-one polymer conjugates
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
CA2462200A1 (fr) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetiques de metallopeptides biologiquement actifs
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
RU2324696C2 (ru) 2001-08-30 2008-05-20 Ализайм Терапевтикс Лимитед Тиено-(1,3)-оксазин-4-оны, обладающие ингибирующей активностью по отношению к липазе
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2003053944A1 (fr) * 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Composes inhibiteurs de la lipase pancreatique, leur synthese et leur utilisation
WO2004043457A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517572C (fr) 2003-03-07 2011-12-13 Schering Corporation Composes d'azetidinone substitues, leurs formulations et leur utilisation pour traiter l'hypercholesterolemie
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1601668B1 (fr) 2003-03-07 2008-08-27 Schering Corporation Composes d'azetidinone substitues, leurs formulations et utilisations en vue du traitement de l'hypercholesterolemie
CA2530634A1 (fr) * 2003-06-12 2004-12-23 Menachem Rubinstein Procedes permettant de traiter l'obesite et des troubles lies a l'obesite au moyen de composes contenant du tellure et du selenium
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
AU2005298692A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
WO2006116773A2 (fr) * 2005-04-28 2006-11-02 The Regents Of The University Of California Procedes, compositions et composes de modulation de la lipase de monoacylglycerol, de douleurs et de troubles lies au stress
SI1897558T1 (sl) 2005-06-09 2014-03-31 Norgine Bv Trden pripravek 2-heksadeciloksi-6-metil-4h-3,1-benzoksazin-e-on
JP2010254623A (ja) * 2009-04-24 2010-11-11 Takeda Chem Ind Ltd ベンゾオキサジノン化合物の結晶
ES2662710T3 (es) 2010-05-24 2018-04-09 Swedish Oat Fiber Ab Dispersión acuosa que comprende galactolípidos y método de producción de la misma
WO2013092786A1 (fr) 2011-12-23 2013-06-27 Norgine B.V. Compositions comprenant du cetilistat
AU2012101841A4 (en) * 2011-12-23 2013-01-17 Norgine Bv Compositions comprising cetilistat
DE202012104963U1 (de) 2012-12-19 2013-01-14 Norgine B.V. Cetilistat aufweisende Zusammensetzungen
CN103936687B (zh) * 2014-03-24 2016-03-30 重庆东得医药科技有限公司 一种制备西替利司他的方法
CN104374836A (zh) * 2014-09-19 2015-02-25 安徽安科生物工程（集团）股份有限公司 西替利司他及有关杂质的hplc测定方法
CN105622538B (zh) * 2014-10-27 2019-02-01 中国医学科学院药物研究所 一锅法高收率制备新利司他
CN104341370B (zh) * 2014-11-11 2017-02-22 山东创新药物研发有限公司 一种西替利司他的制备方法
CN105566164A (zh) * 2016-01-06 2016-05-11 北京修正创新药物研究院有限公司 一种新利司他杂质的制备方法
CN105669585A (zh) * 2016-01-06 2016-06-15 北京修正创新药物研究院有限公司 一种新利司他的制备方法
WO2018011676A1 (fr) * 2016-07-11 2018-01-18 Symed Labs Limited Nouveaux procédés de préparation de dérivés de 2-oxy-benzoxazinone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE246996C (fr)
US4657893A (en) * 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4745116A (en) * 1985-06-25 1988-05-17 Syntex (U.S.A.) Inc. 2-oxy-4H-3,1-benzoxazin-4-ones and related compounds and pharmaceutical use
US4665070A (en) * 1985-06-25 1987-05-12 Syntex (U.S.A.) Inc. 2-oxy-4H-3,1-benzoxazin-4-ones and pharmaceutical use
DD246996A1 (de) * 1986-02-26 1987-06-24 Univ Leipzig Verfahren zur herstellung von gegebenenfalls substituierten 2-alkoxy- bzw. 2-aroxy-3,1-benzoxazin-4-onen
CA1309556C (fr) * 1987-06-09 1992-10-27 Masayuki Kokubo Composes 4h-3,1-benzoxazin-4-one et leurs compositions pharmaceutiques utilisees pour l'inhibition de proteases de la serine
US5652237A (en) 1994-09-09 1997-07-29 Warner-Lambert Company 2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease for the treatment of inflammatory processes
US5985872A (en) * 1995-05-24 1999-11-16 G.D. Searle & Co. 2-amino-benzoxazinones for the treatment of viral infections
US5776756A (en) * 1995-08-31 1998-07-07 Toyo Hakko Co., Ltd. Fermentation compositions having superoxide dismutating activity and an antihypertensive agent for treatment of constipation each having the superoxide dismutating activity
US6136566A (en) * 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6139833A (en) * 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
US6207371B1 (en) * 1996-10-04 2001-03-27 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
CN1280574A (zh) * 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
US6080576A (en) * 1998-03-27 2000-06-27 Lexicon Genetics Incorporated Vectors for gene trapping and gene activation
AR022204A1 (es) * 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.

Also Published As

Publication number Publication date
CN1315813C (zh) 2007-05-16
HUP0105003A3 (en) 2004-11-29
JP3822439B2 (ja) 2006-09-20
US20080161301A1 (en) 2008-07-03
EP1143977B3 (fr) 2012-10-24
US20110065697A1 (en) 2011-03-17
JP2002534388A (ja) 2002-10-15
US7858617B2 (en) 2010-12-28
AU765147C (en) 2007-05-31
HK1103928A1 (en) 2007-12-28
ES2240052T3 (es) 2005-10-16
AU765147B2 (en) 2003-09-11
HK1047588B (zh) 2007-08-24
CA2359819C (fr) 2008-08-12
SI1143977T1 (fr) 2005-08-31
CN1359378A (zh) 2002-07-17
KR100678998B1 (ko) 2007-02-07
RU2245331C2 (ru) 2005-01-27
NZ512740A (en) 2003-10-31
HUP0105003A2 (en) 2002-06-29
CN1915981B (zh) 2011-09-28
EP1143977A1 (fr) 2001-10-17
US20030027821A1 (en) 2003-02-06
CA2359819A1 (fr) 2000-07-13
US20030195206A1 (en) 2003-10-16
PT1143977E (pt) 2005-08-31
AU1884600A (en) 2000-07-24
DE60019555C5 (de) 2009-07-09
WO2000040247A8 (fr) 2001-02-15
ES2240052T7 (es) 2013-02-14
AR022204A1 (es) 2002-09-04
PL207383B1 (pl) 2010-12-31
CN1915981A (zh) 2007-02-21
DE60019555T2 (de) 2006-02-23
DE60019555D1 (de) 2005-05-25
US7825113B2 (en) 2010-11-02
EP1143977B1 (fr) 2005-04-20
US8877750B2 (en) 2014-11-04
DK1143977T3 (da) 2005-08-15
NO20013381D0 (no) 2001-07-06
US6624161B2 (en) 2003-09-23
WO2000040247A1 (fr) 2000-07-13
NO20013381L (no) 2001-09-07
ATE293447T1 (de) 2005-05-15
MY122578A (en) 2006-04-29
NO333922B1 (no) 2013-10-21
WO2000040247A9 (fr) 2002-10-24
MXPA01006921A (es) 2003-06-04
KR20020000542A (ko) 2002-01-05
HK1047588A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
EP1284728A4 (fr) Medicaments destines au traitement de l'obesite
EP1165110A4 (fr) Antagonistes de hmg1 destines au traitement d'etats inflammatoires
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
EP1534074A4 (fr) Polytherapie pour le traitement de l'obesite
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DZ2396A1 (fr) Traitement de l'eau
ATE512594T1 (de) Verbesserung des zustandes älterer haustiere
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
EP1240552A4 (fr) Compositions de photoresine aptes au traitement a l'eau
EP1448193A4 (fr) Composes therapeutiques pour le traitement d'etats dyslipidemiques
EP1156799A4 (fr) Traitement de la bpco
FR2758465B1 (fr) Composition pour le traitement de l'amiante
NO20013596L (no) Slambehandling
MA25501A1 (fr) Traitement de l'endometriosis ou de la sterilite ou amelioration de la fertilite.
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
EP1458694A4 (fr) Composes therapeutiques destines au traitement d'etats dyslipidemiques
EP1389044A4 (fr) Agonistes ou ligands ppar-alpha-gamma destines au traitement d'inflammations
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine
EP1207550A4 (fr) Techniques d'attaque et de traitement au plasma
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
ATE251167T1 (de) Oxazinocarbazole zur behandlung von cns- erkrankungen
MA25509A1 (fr) Composition destinee au traitement de l'hepatite c